CSIMarket
 


Procyon Corporation  (PCYN)
Other Ticker:  
 

Procyon's Quick Ratio

PCYN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 1.44 below Procyon Corporation average.

Within Major Pharmaceutical Preparations industry 138 other companies have achieved higher Quick Ratio than Procyon in second quarter 2023. While Quick Ratio total ranking has improved so far during the II Quarter 2023 to 817, from total ranking in the first quarter 2023 at 1345.

Explain Quick Ratio?
How much Cash & cash equivalents PCYN´s has?
What are PCYN´s Current Liabilities?


PCYN Quick Ratio (Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
Y / Y Current Liabilities Change 19.22 % 19.04 % -2.66 % -5.38 % 14.04 %
Y / Y Cash & cash equivalent Change -5.35 % 11.93 % -2.66 % -19.14 % -18.51 %
Quick Ratio MRQ 1.44 1.7 1.62 1.35 1.81
PCYN's Total Ranking # 817 # 1345 # 1503 # 1722 # 1669
Seq. Current Liabilities Change 2.59 % -9.22 % -4.27 % 33.71 % 2.43 %
Seq. Cash & cash equivalent Change -13.45 % -4.41 % 14.92 % -0.45 % 2.36 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 139
Healthcare Sector # 279
Overall Market # 815


Quick Ratio Statistics
High Average Low
4.61 2.02 0.24
(Sep 30 2018)   (Jun 30 2016)




Financial Statements
Procyon's Current Liabilities $ 1 Millions Visit PCYN's Balance sheet
Procyon's Cash & cash equivalent $ 1 Millions Visit PCYN's Balance sheet
Source of PCYN's Sales Visit PCYN's Sales by Geography


Cumulative Procyon's Quick Ratio

PCYN's Quick Ratio for the trailling 12 Months

PCYN Quick Ratio

(Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth 19.22 % 19.04 % -2.66 % -5.38 % 14.04 %
Y / Y Cash & cash equivalent TTM Growth -5.35 % 11.93 % -2.66 % -19.14 % -18.51 %
Quick Ratio TTM 1.52 1.6 1.62 1.62 1.69
Total Ranking TTM # 218 # 2228 # 3811 # 1279 # 161
Seq. Current Liabilities TTM Growth 2.59 % -9.22 % -4.27 % 33.71 % 2.43 %
Seq. Cash & cash equivalent TTM Growth -13.45 % -4.41 % 14.92 % -0.45 % 2.36 %


On the trailing twelve months basis Due to rise in Current Liabilities in the II Quarter 2023 to $0.58 millions, cumulative Quick Ratio decreased to 1.52 above the PCYN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 39 other companies have achieved higher Quick Ratio than Procyon. While Quick Ratio overall ranking has improved so far to 218, from total ranking during the twelve months ending first quarter 2023 at 2228.

Explain Quick Ratio?
How much Cash & cash equivalents PCYN´s has?
What are PCYN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 40
Healthcare Sector # 74
Within the Market # 218


trailing twelve months Quick Ratio Statistics
High Average Low
3.4 1.44 0.57
(June 30. 2014)   (Mar 31 2017)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Corvus Pharmaceuticals Inc   3.95 $ 27.149  Millions$ 6.869  Millions
Arcutis Biotherapeutics Inc   3.93 $ 183.463  Millions$ 46.668  Millions
Aclaris Therapeutics Inc   3.90 $ 119.106  Millions$ 30.526  Millions
United Therapeutics Corporation  3.89 $ 2,994.100  Millions$ 769.000  Millions
Regeneron Pharmaceuticals Inc   3.66 $ 10,844.800  Millions$ 2,964.500  Millions
Ardelyx Inc   3.66 $ 184.299  Millions$ 50.393  Millions
Citius Pharmaceuticals Inc   3.65 $ 20.384  Millions$ 5.579  Millions
Benitec Biopharma Inc   3.55 $ 20.399  Millions$ 5.746  Millions
Vanda Pharmaceuticals Inc   3.53 $ 135.821  Millions$ 38.460  Millions
Corcept Therapeutics Inc  3.52 $ 368.221  Millions$ 104.505  Millions
Proqr Therapeutics N v   3.48 $ 133.196  Millions$ 38.307  Millions
Schrodinger Inc   3.46 $ 463.003  Millions$ 133.673  Millions
Moleculin Biotech Inc   3.46 $ 23.550  Millions$ 6.815  Millions
Context Therapeutics Inc   3.45 $ 14.450  Millions$ 4.192  Millions
Theriva Biologics inc   3.44 $ 23.177  Millions$ 6.738  Millions
Blueprint Medicines Corporation  3.31 $ 710.641  Millions$ 214.923  Millions
Kiniksa Pharmaceuticals ltd   3.24 $ 206.371  Millions$ 63.666  Millions
Travere Therapeutics Inc   3.19 $ 566.851  Millions$ 177.908  Millions
Deciphera Pharmaceuticals Inc   3.16 $ 306.216  Millions$ 96.771  Millions
Vertex Pharmaceuticals Inc  3.16 $ 11,218.300  Millions$ 3,547.400  Millions
Revance Therapeutics Inc   2.85 $ 254.465  Millions$ 89.224  Millions
Hookipa Pharma inc   2.79 $ 117.096  Millions$ 41.988  Millions
G1 Therapeutics Inc   2.76 $ 82.156  Millions$ 29.716  Millions
Mersana Therapeutics Inc   2.74 $ 174.561  Millions$ 63.637  Millions
Precigen Inc   2.73 $ 62.855  Millions$ 22.985  Millions
Arrowhead Pharmaceuticals Inc   2.69 $ 162.064  Millions$ 60.302  Millions
Paxmedica Inc   2.62 $ 4.711  Millions$ 1.795  Millions
Alnylam Pharmaceuticals Inc   2.51 $ 2,428.204  Millions$ 967.786  Millions
Acurx Pharmaceuticals inc   2.46 $ 7.474  Millions$ 3.042  Millions
Bioxcel Therapeutics Inc   2.39 $ 65.221  Millions$ 27.267  Millions

Date modified: 2024-02-23T13:02:20+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com